Karen Flynn

Karen Flynn filed 60 disclosures for five US companies, from January 5, 2016 to June 26, 2026: West Pharmaceutical Services Inc (Sr VP & Chief Commercial Offic, 31 filings), Catalent, Inc. (Pres. Biologics & CCO, 11), Quanterix Corp (Director, 8), Societal CDMO, Inc. (Director, 5) and Sotera Health Co (Director, 3).

Seven sales represent EUR 3,641,119, with a median of EUR 126,806. Two of them, at West, dominate: EUR 2,049,336 on August 7, 2018 and EUR 1,079,032 on September 6, 2016. The third is that of January 10, 2022 at Catalent (EUR 253,950). A single purchase is recorded, of EUR 5,152, on December 16, 2016 at Societal CDMO, which is 13% of the market trades. The record also holds 49 share grants and 3 option exercises.

The volume peaks in 2016 (14 filings) and 2017 (12), then settles at 2 to 4 a year since 2023. Four filings fall in the last twelve months, one of them a sale. They appear a median of 3 days after the trade.

Flynn's own market trades within 30 days of colleagues at Catalent, Inc. number 4, 3 and 3, all in the same direction. Colleagues in order: Ricci S. Whitlow, Alessandro Maselli and Aristippos Gennadios.